Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CREAD: Crenezumab in Prodromal to Mild Alzheimer's Disease
NCT02670083Phase 3Terminated
- Sponsor
- Roche
- Start
- Mar 2016
- Primary completion
- May 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 30
01
Overview
A Phase 3 trial of crenezumab in Alzheimer's disease (AD), sponsored by Roche. Started Mar 2016; status: terminated.
02
Drugs
crenezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02670083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02670083.